• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立并验证一个列线图模型以预测结直肠癌肝转移患者中哪些患者将从原发灶切除中获益。

Development and validation of a nomogram to predict which patients with colorectal cancer liver metastases would benefit from primary tumor resection.

机构信息

Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

出版信息

Int J Colorectal Dis. 2023 May 27;38(1):144. doi: 10.1007/s00384-023-04426-5.

DOI:10.1007/s00384-023-04426-5
PMID:37237238
Abstract

PURPOSE

The use of primary tumor resection (PTR) in the treatment of colorectal cancer liver metastases (CRLM) patients has become increasingly controversial. Our goal is to establish a nomogram to screen for the candidates that would benefit from PTR in CRLM patients.

METHODS

The Surveillance, Epidemiology, and End Results (SEER) database was searched for 8366 patients with colorectal liver cancer metastases (CRLM) from 2010 to 2015. Overall survival (OS) rates were calculated using the Kaplan-Meier curve. After propensity score matching (PSM), predictors were analyzed by logistic regression analysis, and a nomogram was created to predict for survival benefit of PTR using R software.

RESULTS

After PSM, there were 814 patients in both PTR group and non-PTR group, respectively. The median OS time in the PTR group was 26 months (95%CI = 23.33 ~ 28.67) and the median OS time in the non-PTR group was 15 months (95%CI = 13.36 ~ 16.64). The Cox regression analysis found that PTR was an independent predictive factor (HR = 0.46, 0.41 ~ 0.52) for OS. Additionally, logistic regression was used to study the factors impacting PTR benefit, and the results showed that CEA (P = 0.016), chemotherapy (P < 0.001), N stage (P < 0.001), histological grade (P < 0.001), and lung metastasis (P = 0.001) are independent predictive factors affecting the therapeutic outcome of PTR in patients with CRLM. The developed nomogram displayed good discriminative ability in predicting the beneficial probability of PTR surgery, with the area under the curve (AUC) values of 0.801 in training set and 0.739 in validation set respectively.

CONCLUSION

We developed a nomogram that predicts the survival benefits of PTR in CRLM patients with relatively high accuracy, and quantifies the predictive factors for PTR-related benefits.

摘要

目的

在结直肠癌肝转移(CRLM)患者的治疗中,采用原发肿瘤切除术(PTR)的做法越来越受到争议。我们的目标是建立一个列线图,筛选出从 CRLM 患者 PTR 中获益的候选者。

方法

从 2010 年至 2015 年,利用监测、流行病学和最终结果(SEER)数据库检索 8366 例结直肠肝转移(CRLM)患者。采用 Kaplan-Meier 曲线计算总生存率(OS)。在进行倾向评分匹配(PSM)后,通过逻辑回归分析对预测因子进行分析,并使用 R 软件创建一个列线图,以预测 PTR 对生存的获益。

结果

在 PSM 后,分别有 814 例患者进入 PTR 组和非 PTR 组。PTR 组的中位 OS 时间为 26 个月(95%CI=23.3328.67),非 PTR 组的中位 OS 时间为 15 个月(95%CI=13.3616.64)。Cox 回归分析发现 PTR 是 OS 的独立预测因素(HR=0.46,0.41~0.52)。此外,使用逻辑回归研究影响 PTR 获益的因素,结果显示癌胚抗原(CEA)(P=0.016)、化疗(P<0.001)、N 期(P<0.001)、组织学分级(P<0.001)和肺转移(P=0.001)是影响 CRLM 患者 PTR 治疗效果的独立预测因素。所开发的列线图在预测 PTR 手术获益的概率方面具有良好的判别能力,在训练集和验证集中的曲线下面积(AUC)值分别为 0.801 和 0.739。

结论

我们开发了一个列线图,可以较准确地预测 CRLM 患者 PTR 的生存获益,并量化了 PTR 相关获益的预测因素。

相似文献

1
Development and validation of a nomogram to predict which patients with colorectal cancer liver metastases would benefit from primary tumor resection.建立并验证一个列线图模型以预测结直肠癌肝转移患者中哪些患者将从原发灶切除中获益。
Int J Colorectal Dis. 2023 May 27;38(1):144. doi: 10.1007/s00384-023-04426-5.
2
Analysis of survival benefit from primary tumor resection and individualized prediction of overall survival for lung cancer patients with bone metastasis: Worth it or not?原发肿瘤切除术对肺癌骨转移患者生存获益的分析及总体生存个体化预测:值得吗?
Asian J Surg. 2024 Jan;47(1):333-349. doi: 10.1016/j.asjsur.2023.08.198. Epub 2023 Sep 21.
3
A dynamic visualization clinical tool constructed and validated based on the SEER database for screening the optimal surgical candidates for bone metastasis in primary kidney cancer.基于 SEER 数据库构建和验证的动态可视化临床工具,用于筛选原发性肾癌骨转移的最佳手术候选者。
Sci Rep. 2024 Feb 12;14(1):3561. doi: 10.1038/s41598-024-54085-x.
4
Identification of optimal primary tumor resection candidates for metastatic gastric cancer: Nomograms based on propensity score matching.基于倾向评分匹配的转移性胃癌最佳原发灶切除候选者的识别:列线图。
Cancer Med. 2023 Jun;12(12):13063-13075. doi: 10.1002/cam4.5983. Epub 2023 Apr 25.
5
Clinical characteristic-assisted surgical benefit stratification for resection of primary tumor in patients with advanced primary malignant bone neoplasms: a population-based propensity score-matched analysis.晚期原发性恶性骨肿瘤患者原发性肿瘤切除的临床特征辅助手术获益分层:一项基于人群的倾向评分匹配分析
Front Oncol. 2023 Sep 6;13:960502. doi: 10.3389/fonc.2023.960502. eCollection 2023.
6
Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.术后辅助化疗对于改善同时性切除的结直肠癌肝转移患者的长期生存率至关重要。
J Gastroenterol Hepatol. 2024 May;39(5):908-919. doi: 10.1111/jgh.16504. Epub 2024 Feb 7.
7
Survival Benefits of Postoperative Chemotherapy in Patients With Colorectal Mucinous Adenocarcinoma: An Analysis Utilizing Propensity Score Matching From the Surveillance, Epidemiology, and End Results Database.术后化疗对结直肠黏液腺癌患者生存获益的影响:基于监测、流行病学和最终结果数据库的倾向评分匹配分析。
Am Surg. 2024 Nov;90(11):2969-2984. doi: 10.1177/00031348241257469. Epub 2024 Jun 7.
8
A population-based predictive model identifying optimal candidates for primary and metastasis resection in patients with colorectal cancer with liver metastatic.一种基于人群的预测模型,用于识别肝转移结直肠癌患者进行原发灶和转移灶切除的最佳候选者。
Front Oncol. 2022 Oct 7;12:899659. doi: 10.3389/fonc.2022.899659. eCollection 2022.
9
A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era.一种用于预测可切除结直肠癌肝转移生存结局的预后评分系统。
Ann Surg Oncol. 2021 Nov;28(12):7709-7718. doi: 10.1245/s10434-021-10143-6. Epub 2021 May 22.
10
Who are optimal candidates for primary tumor resection in patients with metastatic gastric adenocarcinoma? A population-based study.转移性胃腺癌患者中哪些是原发肿瘤切除术的最佳候选者?一项基于人群的研究。
PLoS One. 2024 Jan 24;19(1):e0292895. doi: 10.1371/journal.pone.0292895. eCollection 2024.

引用本文的文献

1
Integrative Predictive Nomograms for Treatment Decision-Making in Resectable Synchronous Colorectal Liver Metastases.用于可切除同步性结直肠癌肝转移治疗决策的综合预测列线图
J Cancer. 2025 Jan 27;16(5):1451-1465. doi: 10.7150/jca.107194. eCollection 2025.
2
Prognostic prediction and treatment options for gastric signet ring cell carcinoma: a SEER database analysis.胃印戒细胞癌的预后预测与治疗选择:一项监测、流行病学和最终结果(SEER)数据库分析
Front Oncol. 2024 Oct 21;14:1473798. doi: 10.3389/fonc.2024.1473798. eCollection 2024.
3
Clinical Prediction Models for Prognosis of Colorectal Liver Metastases: A Comprehensive Review of Regression-Based and Machine Learning Models.

本文引用的文献

1
Clinical management of metastatic colorectal cancer in the era of precision medicine.精准医学时代转移性结直肠癌的临床管理。
CA Cancer J Clin. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. Epub 2022 Apr 26.
2
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.结肠癌临床实践指南(2021 年第 2 版),NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359. doi: 10.6004/jnccn.2021.0012.
3
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
结直肠癌肝转移预后的临床预测模型:基于回归和机器学习模型的综合综述
Cancers (Basel). 2024 Apr 25;16(9):1645. doi: 10.3390/cancers16091645.
4
Complete Blood Count Alterations Prior to the Diagnosis of Colorectal Cancer May Help in the Detection of Synchronous Liver Metastases.结直肠癌诊断前全血细胞计数的改变可能有助于检测同时性肝转移。
J Clin Med. 2023 Oct 15;12(20):6540. doi: 10.3390/jcm12206540.
原发肿瘤切除联合化疗对比单纯化疗治疗无症状、同步不可切除转移结直肠癌患者(JCOG1007;iPACS):一项随机临床试验。
J Clin Oncol. 2021 Apr 1;39(10):1098-1107. doi: 10.1200/JCO.20.02447. Epub 2021 Feb 9.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Influence of primary tumor location and resection on survival in metastatic colorectal cancer.原发性肿瘤位置及切除对转移性结直肠癌生存的影响
World J Gastrointest Oncol. 2020 Nov 15;12(11):1296-1310. doi: 10.4251/wjgo.v12.i11.1296.
6
Pulmonary Metastasectomy in Colorectal Cancer: the PulMiCC randomised controlled trial.结直肠癌肺转移灶切除术:PulMiCC随机对照试验
Br J Surg. 2020 Oct;107(11):e489-e490. doi: 10.1002/bjs.11948. Epub 2020 Aug 21.
7
A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis.预测低级别子宫内膜间质肉瘤患者总生存期的列线图:基于人群的分析。
Cancer Commun (Lond). 2020 Jul;40(7):301-312. doi: 10.1002/cac2.12067. Epub 2020 Jun 18.
8
Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed.结直肠癌肺转移切除术:93 例随机对照患者的更新分析-对照生存率比之前预期的要好得多。
Colorectal Dis. 2020 Oct;22(10):1314-1324. doi: 10.1111/codi.15113. Epub 2020 Jun 14.
9
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.晚期结直肠癌患者的治疗:美国临床肿瘤学会资源分层指南
JCO Glob Oncol. 2020 Mar;6:414-438. doi: 10.1200/JGO.19.00367.
10
A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study).一项比较不可治愈的 IV 期结直肠癌中单纯化疗与肿瘤初始切除加化疗的随机对照临床试验:JCOG1007(iPACS 研究)。
Jpn J Clin Oncol. 2020 Jan 24;50(1):89-93. doi: 10.1093/jjco/hyz173.